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C O N T I N U E D
Do acetaminophen 
and an NSAID combined
relieve osteoarthritis pain
better than either alone?
■ EVIDENCE-BASED ANSWER
Combining nonsteroidal anti-inflammatory drugs
(NSAIDs) and acetaminophen for short courses
provides more relief of pain in osteoarthritis with-
out an increase in side effects (strength of recom-
mendation [SOR]=B). Combining acetaminophen
at 4 g/d with an NSAID can also decrease the
daily dose of NSAID required for pain relief, thus
reducing the potential risk from higher-dose
NSAID therapy (SOR=B). 
Over the long term, however, this combination
may increase the risk of upper gastrointestinal
(GI) bleeding more than that conferred by the
NSAID alone (SOR=B). If combination therapy 
is necessary, limiting the dose of acetaminophen
to ≤2 g/d minimizes gastrointestinal toxicity.
Acetaminophen alone at the lowest dose to pro-
vide pain relief is the safest pharmacologic choice
for patients with osteoarthritis.
■ EVIDENCE SUMMARY
Clinical guidelines for osteoarthritis recommend
acetaminophen as first-line therapy followed by
an NSAID or cyclooxygenase-2 (COX-2) inhibitor,
and many patients are treated with combination
therapy. 
Several small randomized controlled trials
have compared the individual efficacy of NSAIDs
and acetaminophen in osteoarthritis and have
found that both provide more pain relief than
placebo.1–3 There is a trend toward improved pain
relief with NSAIDs compared with acetaminophen
in the initial treatment period; however, few long-
term studies of efficacy have been reported. One
randomized controlled trial comparing 750 mg/d
naproxen (Aleve, Naprosyn) with 2600 mg/d acet-
aminophen for 2 years found similar pain relief for
both medications and a dropout rate of 65% in
both groups.2 Similar numbers of persons taking
acetaminophen or naproxen dropped out because
of adverse effects (20%) or lack of efficacy (19%),
and no difference was seen in functional improve-
ment between the 2 groups. 
A 6-week randomized double-blind crossover
trial of 227 patients comparing 75 mg diclofenac
and 200 mg misoprostol (Arthrotec) with aceta-
minophen 4 g/d found the diclofenac-misoprostol
combination provided more pain control than acet-
aminophen alone. Adverse events were slightly
more common in the diclofenac group (54% vs
46%; P=.046).4
The COX-2 inhibitors rofecoxib (Vioxx) and
celecoxib (Celebrex) have been shown to provide
equal pain relief compared with naproxen for
patients with osteoarthritis.5 One industry-spon-
sored randomized trial found rofecoxib superior to
celecoxib, and both superior to acetaminophen in
treatment of osteoarthritis pain.6 There was no
difference in the incidence of side effects among
the 3 medications. Thirty percent of patients tak-
ing 4 g/d acetaminophen discontinued the study
because of lack of efficacy, compared with 20% of
those taking either celecoxib or rofecoxib.6
Few studies have evaluated the safety or effi-
cacy of the combination of NSAIDs and acetamin-
ophen in osteoarthritis. One double-blind, double-
dummy crossover trial of 18 patients with
osteoarthritis of the hip compared naproxen at
doses of 500 mg and 1000 mg, with and without 4
g/d of acetaminophen, and 1500 mg/d of naproxen
alone over 5 one-week trial periods.7 Adding acet-
aminophen improved patient-reported pain scores
compared with naproxen alone. Higher doses of
naproxen alone provided less pain relief than a
lower dose of naproxen combined with acetamino-
phen. GI side effects increased with the increase
in naproxen dose, but were unaffected by the addi-
tion of acetaminophen. Functional ability was not
affected during this short study. A similar study by
the same researchers of patients with rheumatoid
arthritis found similar results.7
One randomized, double-blind, crossover trial
compared single doses of tolmetin (Tolectin, 100,
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150, 200 mg) and acetaminophen (400 mg) alone
and in combination with placebo in the control of
experimentally induced pain (thermal and electri-
cal stimulation). Acetaminophen alone did not 
differ from placebo in pain control; however, the
combinations of acetaminophen with tolmetin 
provided similar pain relief to higher doses of 
tolmetin alone.8 No studies have evaluated the
efficacy or safety of acetaminophen combined
with rofecoxib or celecoxib.
Regarding the risks of combining acetamino-
phen with NSAIDs, 1 nested case-control study
based on the entire enrollment panel of the
British National Health Service characterized
the risk of upper GI side effects among persons
taking NSAIDs or acetaminophen alone or in
combination. The study evaluated medications
in use at the time of an upper GI bleed, control-
ling for age, sex, and concomitant medications
(corticosteroids, H2 receptor antagonists,
omeprazole, anticoagulants, and others) and
excluding patients with varices, alcohol-related
disorders, liver disease, and cancer; no attempt
was made to control other comorbidities. The
relative risk of upper GI perforation or bleeding
for patients taking ≥2g/d acetaminophen or
high-dose NSAIDs was 2.4 (95% confidence
interval [CI], 1.7–3.5) and 3.6 (95% CI,
2.9–4.3), respectively. Concomitant use of an
NSAID with ≥2 g/d of acetaminophen showed a
relative risk of  upper GI perforation or bleed of
16.6 (95% CI, 11.0–24.9). Acetaminophen doses
<2 g/d conferred no additional risk for serious
upper GI side effects.9
A systematic review of selective COX-2
inhibitors vs naproxen found fewer endoscopi-
cally detected ulcers in patients taking celecox-
ib but no difference in serious gastrointestinal
bleeds.5 A meta-analysis of randomized con-
trolled trials found a higher incidence of serious
thrombotic cardiovascular events among
patients taking COX-2 inhibitors compared with
naprosyn.10 The safety profile of rofecoxib and
celecoxib in the long-term treatment of pain is
not fully understood at this time.
■ RECOMMENDATIONS FROM OTHERS
The American College of Rheumatology (ACR)
recommends acetaminophen up to 4 g/d as 
a first-line pharmacologic treatment for
osteoarthritis of the hip and knee, and advises
NSAIDs be used at the lowest effective dose if
they are necessary for pain control.11 The ACR
does not specifically comment on combining
NSAID and acetaminophen use. 
The American Academy of Orthopaedic
Surgeons recommends initial use of an NSAID or
acetaminophen, but does not comment on the
combination of NSAIDs and acetaminophen.12
Jennifer J. Buescher, MD, Susan Meadows, MLS,
Department of Family and Community Medicine, University of
Missouri–Columbia
■ CLINICAL COMMENTARY:
Adding acetaminophen may be more 
desirable than switching NSAIDs 
Compared with NSAIDs, acetaminophen has a
complementary analgesic mechanism of action
and can be safely used in many patients.
Additive effects of acetaminophen have not
been well described with all NSAIDs (eg, COX-
2 inhibitors); however, this combination is inex-
pensive and overall appears to effectively aug-
ment analgesia when combined with NSAIDs.
Although observational data demonstrate an
increased risk of upper GI bleeding with this
combination, selection bias (higher-risk patients
being on combination therapy) could reasonably
explain this association. Adding acetaminophen
may be more desirable than switching NSAIDs
for patients with osteoarthritis that have a par-
tial response to their current NSAID therapy. 
Joseph Saseen, PharmD, FCCP, BCPS, University
of Colorado Health Sciences Center, Denver
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DRUG BRAND NAMES
Amoxicillin • Amoxil, Biomox, Polymox, Trimox, Wymox
Cephalexin • Biocef, Keflex
Celecoxib • Celebrex
Diclofenac/Misoprostol • Arthrotec
Ipratropium • Atrovent
Labetalol • Trandate
Methyldopa • Aldomet
Naproxen • Aleve, Anaprox, Naprosyn
Nitrofurantoin • Furadantin, Macrobid, Macrodantin
Rofecoxib • Vioxx
Tiotropium • Spiriva
Tolmetin • Tolectin
Triamcinalone • Aristocort, Atolone, Kenacort
Sulfamethoxazole/Trimethoprim • Bactrim, Cotrim, 
Septra, Sulfatrim
Sulfisoxazole • Gantrisin 
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